help button home button Am J Pathol R & D Systems
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhou, X.-P.
Right arrow Articles by Eng, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhou, X.-P.
Right arrow Articles by Eng, C.
(American Journal of Pathology. 2000;157:1123-1128.)
© 2000 American Society for Investigative Pathology

Regular Articles

Epigenetic PTEN Silencing in Malignant Melanomas without PTEN Mutation

Xiao-Ping Zhou*, Oliver Gimm*, Heather Hampel*, Theodore Niemann{dagger}, Michael J. Walker{ddagger} and Charis Eng*§

From the Clinical Cancer Genetics and Human Cancer Genetics Programs, Comprehensive Cancer Center*
and Division of Human Genetics, Department of Internal Medicine, the Department of Pathology,{dagger}
and the Division of Surgical Oncology,{ddagger}
Department of Surgery, The Ohio State University, Columbus, Ohio; and the Cancer Research Campaign Human Cancer Genetics Research Group,§
University of Cambridge, Cambridge, United Kingdom

A tumor suppressor gene at 10q 23.3, designated PTEN, encoding a dual specificity phosphatase with lipid and protein phosphatase activity, has been shown to play an important role in the pathogenesis of a variety of human cancers. Germline mutations in PTEN cause Cowden syndrome (CS), which is characterized by multiple hamartomas and a high risk of breast and thyroid cancers. Frequent loss of heterozygosity at 10q is found in both early and advanced-stage sporadic melanomas; however, mutations or deletions in PTEN are detected mainly in melanoma cell lines. In this study, we examined PTEN expression in 34 unselected sporadic melanomas (4 primary melanomas, 30 metastases) using immunohistochemistry and correlated this with the results of structural studies of this gene. Immunostaining of 34 melanoma samples revealed no PTEN expression in 5 (15%) and low PTEN expression in 17 (50%), whereas the rest of the tumors (35%) had high levels of expression. Hemizygous deletion was found in 32% of the tumors but neither intragenic PTEN mutation nor biallelic deletion was found in any of the samples. Of the 5 melanomas showing no PTEN expression, 4 had no mutation or deletion of PTEN. Of the 13 tumors having weak PTEN immunoreactivity and informative loss of heterozygosity results, 6 had evidence of hemizygous allelic loss of PTEN while the remaining 7 had intact PTEN. These results strongly support PTEN as a major tumor suppressor on 10q involved in melanoma tumorigenesis and suggest an epigenetic mechanism of biallelic functional inactivation not previously observed in other cancers where PTEN might be involved.




This article has been cited by other articles:


Home page
 Mol. Cell. Biol.Home page
M. Escriva, S. Peiro, N. Herranz, P. Villagrasa, N. Dave, B. Montserrat-Sentis, S. A. Murray, C. Franci, T. Gridley, I. Virtanen, et al.
Repression of PTEN Phosphatase by Snail1 Transcriptional Factor during Gamma Radiation-Induced Apoptosis
Mol. Cell. Biol., March 1, 2008; 28(5): 1528 - 1540.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Mirmohammadsadegh, A. Marini, S. Nambiar, M. Hassan, A. Tannapfel, T. Ruzicka, and U. R. Hengge
Epigenetic Silencing of the PTEN Gene in Melanoma.
Cancer Res., July 1, 2006; 66(13): 6546 - 6552.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. G. Haluska, H. Tsao, H. Wu, F. S. Haluska, A. Lazar, and V. Goel
Genetic alterations in signaling pathways in melanoma.
Clin. Cancer Res., April 1, 2006; 12(7): 2301s - 2307s.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. H. Abdel-Rahman, Y. Yang, X.-P. Zhou, E. L. Craig, F. H. Davidorf, and C. Eng
High Frequency of Submicroscopic Hemizygous Deletion Is a Major Mechanism of Loss of Expression of PTEN in Uveal Melanoma
J. Clin. Oncol., January 10, 2006; 24(2): 288 - 295.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. Hill, Y. Song, R. D. Cardiff, and T. Van Dyke
Heterogeneous Tumor Evolution Initiated by Loss of pRb Function in a Preclinical Prostate Cancer Model
Cancer Res., November 15, 2005; 65(22): 10243 - 10254.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
W. M. Gallagher, O. E. Bergin, M. Rafferty, Z. D. Kelly, I.-M. Nolan, E. J.P. Fox, A. C. Culhane, L. McArdle, M. F. Fraga, L. Hughes, et al.
Multiple markers for melanoma progression regulated by DNA methylation: insights from transcriptomic studies
Carcinogenesis, November 1, 2005; 26(11): 1856 - 1867.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Mikhail, E. Velazquez, R. Shapiro, R. Berman, A. Pavlick, L. Sorhaindo, J. Spira, C. Mir, K. S. Panageas, D. Polsky, et al.
PTEN Expression in Melanoma: Relationship with Patient Survival, Bcl-2 Expression, and Proliferation
Clin. Cancer Res., July 15, 2005; 11(14): 5153 - 5157.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. Fassnacht, D. Weismann, S. Ebert, P. Adam, M. Zink, F. Beuschlein, S. Hahner, and B. Allolio
AKT Is Highly Phosphorylated in Pheochromocytomas But Not in Benign Adrenocortical Tumors
J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 4366 - 4370.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Goel, C. N. Arnold, D. Niedzwiecki, J. M. Carethers, J. M. Dowell, L. Wasserman, C. Compton, R. J. Mayer, M. M. Bertagnolli, and C. R. Boland
Frequent Inactivation of PTEN by Promoter Hypermethylation in Microsatellite Instability-High Sporadic Colorectal Cancers
Cancer Res., May 1, 2004; 64(9): 3014 - 3021.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Bertherat, L. Groussin, F. Sandrini, L. Matyakhina, T. Bei, S. Stergiopoulos, T. Papageorgiou, I. Bourdeau, L. S. Kirschner, C. Vincent-Dejean, et al.
Molecular and Functional Analysis of PRKAR1A and its Locus (17q22-24) in Sporadic Adrenocortical Tumors: 17q Losses, Somatic Mutations, and Protein Kinase A Expression and Activity
Cancer Res., September 1, 2003; 63(17): 5308 - 5319.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. Choe, S. Horvath, T. F. Cloughesy, K. Crosby, D. Seligson, A. Palotie, L. Inge, B. L. Smith, C. L. Sawyers, and P. S. Mischel
Analysis of the Phosphatidylinositol 3'-Kinase Signaling Pathway in Glioblastoma Patients in Vivo
Cancer Res., June 1, 2003; 63(11): 2742 - 2746.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. M. Stahl, M. Cheung, A. Sharma, N. R. Trivedi, S. Shanmugam, and G. P. Robertson
Loss of PTEN Promotes Tumor Development in Malignant Melanoma
Cancer Res., June 1, 2003; 63(11): 2881 - 2890.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. J. Arboleda, J. F. Lyons, F. F. Kabbinavar, M. R. Bray, B. E. Snow, R. Ayala, M. Danino, B. Y. Karlan, and D. J. Slamon
Overexpression of AKT2/Protein Kinase B{beta} Leads to Up-Regulation of {beta}1 Integrins, Increased Invasion, and Metastasis of Human Breast and Ovarian Cancer Cells
Cancer Res., January 1, 2003; 63(1): 196 - 206.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
X.-P. Zhou, A. Loukola, R. Salovaara, M. Nystrom-Lahti, P. Peltomaki, A. de la Chapelle, L. A. Aaltonen, and C. Eng
PTEN Mutational Spectra, Expression Levels, and Subcellular Localization in Microsatellite Stable and Unstable Colorectal Cancers
Am. J. Pathol., August 1, 2002; 161(2): 439 - 447.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
L.-P. Weng, J. L. Brown, K. M. Baker, M. C. Ostrowski, and C. Eng
PTEN blocks insulin-mediated ETS-2 phosphorylation through MAP kinase, independently of the phosphoinositide 3-kinase pathway
Hum. Mol. Genet., July 15, 2002; 11(15): 1687 - 1696.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Cell Physiol.Home page
J. E. Dumont, S. Dremier, I. Pirson, and C. Maenhaut
Cross signaling, cell specificity, and physiology
Am J Physiol Cell Physiol, July 1, 2002; 283(1): C2 - C28.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Fernandez and C. Eng
The Expanding Role of PTEN in Neoplasia: A Molecule for All Seasons? : Commentary re: M. A. Davies, et al., Adenoviral-mediated Expression of MMAC/PTEN Inhibits Proliferation and Metastasis of Human Prostate Cancer Cells. Clin. Cancer Res., 8: 1904-1914, 2002.
Clin. Cancer Res., June 1, 2002; 8(6): 1695 - 1698.
[Abstract] [Full Text] [PDF]

Home page
 Vet PatholHome page
R. A. Levine, T. Forest, and C. Smith
Tumor Suppressor PTEN is Mutated in Canine Osteosarcoma Cell Lines and Tumors
Vet. Pathol., May 1, 2002; 39(3): 372 - 378.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
M. A. Zysman, W. B. Chapman, and B. Bapat
Considerations When Analyzing the Methylation Status of PTEN Tumor Suppressor Gene
Am. J. Pathol., March 1, 2002; 160(3): 795 - 800.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
V. N. Ivanov, M. Krasilnikov, and Z.'e. Ronai
Regulation of Fas Expression by STAT3 and c-Jun Is Mediated by Phosphatidylinositol 3-Kinase-AKT Signaling
J. Biol. Chem., February 8, 2002; 277(7): 4932 - 4944.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M. J. You, D. H. Castrillon, B. C. Bastian, R. C. O'Hagan, M. W. Bosenberg, R. Parsons, L. Chin, and R. A. DePinho
Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice
PNAS, January 24, 2002; (2002) 22632099.
[Abstract] [Full Text] [PDF]

Home page
 Arch Otolaryngol Head Neck SurgHome page
J. I. Lee, J.-C. Soria, K. A. Hassan, A. K. El-Naggar, X. Tang, D. D. Liu, W. K. Hong, and L. Mao
Loss of PTEN Expression as a Prognostic Marker for Tongue Cancer
Arch Otolaryngol Head Neck Surg, December 1, 2001; 127(12): 1441 - 1445.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
G. B. Mills, Y. Lu, and E. C. Kohn
Linking molecular therapeutics to molecular diagnostics: Inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo
PNAS, August 28, 2001; 98(18): 10031 - 10033.
[Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
G. L. Mutter
PTEN, a Protean Tumor Suppressor
Am. J. Pathol., June 1, 2001; 158(6): 1895 - 1898.
[Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
K. Kurose, X.-P. Zhou, T. Araki, S. A. Cannistra, E. R. Maher, and C. Eng
Frequent Loss of PTEN Expression Is Linked to Elevated Phosphorylated Akt Levels, but Not Associated with p27 and Cyclin D1 Expression, in Primary Epithelial Ovarian Carcinomas
Am. J. Pathol., June 1, 2001; 158(6): 2097 - 2106.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Bhoumik, V. Ivanov, and Z.'e. Ronai
Activating Transcription Factor 2-derived Peptides Alter Resistance of Human Tumor Cell Lines to Ultraviolet Irradiation and Chemical Treatment
Clin. Cancer Res., February 1, 2001; 7(2): 331 - 342.
[Abstract] [Full Text]

Home page
 J. Cell Sci.Home page
K. M. Yamada and M. Araki
Tumor suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis
J. Cell Sci., January 7, 2001; 114(13): 2375 - 2382.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
G. Schwartzbauer and J. Robbins
The Tumor Suppressor Gene PTEN Can Regulate Cardiac Hypertrophy and Survival
J. Biol. Chem., September 14, 2001; 276(38): 35786 - 35793.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M. J. You, D. H. Castrillon, B. C. Bastian, R. C. O'Hagan, M. W. Bosenberg, R. Parsons, L. Chin, and R. A. DePinho
Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice
PNAS, February 5, 2002; 99(3): 1455 - 1460.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the American Society for Investigative Pathology.